SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financi...(guarantees of future performance and tha...)

Date:3/11/2009

guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstance.

    Contacts:
    Investor Relations:
    Cameron Associates
    Kevin McGrath
    212.245.4577
    kevin@cameronassoc.com

                                  FINANCIAL HIGHLIGHTS

                                   SCOLR Pharma, Inc.

                                     BALANCE SHEETS

                                                       December 31,
                                                 2008                2007
    ASSETS
      Current Assets
       Cash and cash equivalents           $6,363,243         $11,825,371
       Accounts receivable                    177,253             225,900
       Interest and other receivables           1,157                  16
       Prepaid expenses                       286,539             423,213
         Total current assets               6,828,192          12,474,500

    Property and equipment-net                790,947             748,931
    Intangible assets-net                     557,639             464,023
    Restricted cash                           473,711                   -

                                           $8,650,489         $13,687,454

    LIABILITIES AND STOCKHOLDERS'
     EQUITY
    Current Liabilities
       Accounts payable                      $238,701            $757,420
       Accrued liabilities                    668,694             586,849
       Current portion of term loan            87,850              80,047
         Total current liabilities            995,245           1,424,316

    Long-term portion of term loan             23,269             111,119
 
'/>"/>
SOURCE  SCOLR Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 
Related biology technology :

1. SCOLR Pharma, Inc. Schedules Second Quarter 2008 Financial Results Conference Call for August 7, 2008 at 11:30 A.M. Eastern
2. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
3. SCOLR Pharma, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
4. FDA Issues Complete Response Letter to SCOLR Pharmas Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine
5. GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen
6. Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R)
7. China Biopharma, Inc. Announces New Plan of Operation
8. Meritage Pharma, Inc. Announces Company Formation and $22.5M Series A Financing
9. CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux).
10. Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO
11. Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors